secwatch.observer — SEC 8-K summary
======================================

Issuer:     VERTEX PHARMACEUTICALS INC / MA (VRTX)
CIK:        0000875320
Form:       8-K
Filed at:   2026-02-12T23:59:59+00:00
Accession:  0000875320-26-000034
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Vertex reports FY2025 revenue $12.0B (+9% YoY); guides FY2026 revenue $12.95-13.1B
--------------------------------------------------------------------------------

- FY2025 total revenue $12.0B, up 9% YoY; Q4 revenue $3.19B, up 10% YoY.
- GAAP net income $4.0B in FY2025 vs net loss of $(536)M in 2024; cash $12.3B.
- FY2026 revenue guidance $12.95–$13.1B; non-CF product revenue expected ≥$500M.
- JOURNAVX: >550,000 prescriptions filled in 2025; coverage for >200M U.S. lives.
- Rolling BLA for povetacicept in IgAN on track for completion in H1 2026; ALYFTREK pediatric study completed.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/875320/000087532026000034/0000875320-26-000034-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/875320/000087532026000034/vrtx-20260212.htm
  HTML page:      https://secwatch.observer/filing/0000875320-26-000034

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer